Allarity Therapeutics
ALLR
9 hedge funds and large institutions have $108K invested in Allarity Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.
823% more capital invested
Capital invested by funds: $11.7K → $108K (+$96.1K)
350% more funds holding
Funds holding: 2 → 9 (+7)
0.63% less ownership
Funds ownership: 0.63% → 0% (-0.63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$347K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$134K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$51.8K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$50.7K |
| 5 |
HF
HRT Financial
New York
|
+$45.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$11 |
| 2 |
Morgan Stanley
New York
|
-$2 |
ALLR Hedge Fund Activity: Q2 2024 in Review
9 of the 6,938 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q2 2024, worth a combined $108K — up 823% from $11.7K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ALLR positions and 0 closed out — a net gain of 7 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $347K. The largest seller was Wells Fargo, cutting an estimated $11.
- 9 institutional investors held Allarity Therapeutics (ALLR) as of Q2 2024, up from 2 in Q1 2024.
- Funds reported $108K of Allarity Therapeutics stock for Q2 2024, up 823% quarter-over-quarter.
- 7 funds opened new Allarity Therapeutics positions in Q2 2024 and 0 closed out, a net change of +7 holders.
- The largest Allarity Therapeutics buyer in Q2 2024 was Virtu Financial, an estimated $347K added.
- The largest Allarity Therapeutics seller in Q2 2024 was Wells Fargo, an estimated $11 sold.
Based on aggregated 13F filings for Q2 2024.